(Q37822216)

23 August 2017

1 reference

title

Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs (English)

1 reference

23 August 2017

0 references

0 references

0 references

1 reference

Mehrul Hasnain

1

1 reference

23 August 2017

Sonja K Fredrickson

series ordinal

2

1 reference

23 August 2017

W Victor R Vieweg

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

17 December 2010

1 reference

Journal of Psychopharmacology

23 August 2017

published in

1 reference

23 August 2017

volume

25

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

715-721

1 reference

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Psychological predictors of physical activity in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Patterns of antipsychotic medication use in Australia 2002-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes As

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Management of atypical antipsychotic drug-induced weight gain: focus on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Impaired fasting glucose and impaired glucose tolerance: implications for care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

An update on the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

A Systematic Review of Mortality in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metformin for weight control in pediatric patients on atypical antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110389214

21 January 2018

Identifiers

DOI

10.1177/0269881110389214

1 reference

23 August 2017

1 reference